NetworkNewsBreaks – CytoDyn Inc. (CYDY) Presiden
Post# of 148337
(Total Views: 138)
Posted On: 11/09/2018 7:17:31 PM
NetworkNewsBreaks – CytoDyn Inc. (CYDY) President and CEO Featured in Uptick Newswire’s Stock Day Podcast
Biotechnology company CytoDyn (OTCQB: CYDY) this morning announced the featured interview of its President and CEO Nader Z. Pourhassan, Ph.D. with Stock Day's Everett Jolly. Jolly initiated the discussion by asking about CytoDyn’s PRO 140. The company’s flagship product is a humanized IgG4 monoclonal antibody that is designed to bind to cellular receptor CCR5, which plays various roles with implications in HIV, tumor metastasis and immune signaling. Pending FDA approval, which the company hopes to secure in Q4 2019, Pourhassan indicates that PRO 140 may be available to the public in 2020. "Most biotech companies, when they finish the biologic application, they have an 85% chance to get approved. 9 out of 10 who don't get approved is because of the safety of the product. Our product has received fast track designation due to having great safety among all of the approved drugs," Nader Z. Pourhassan, Ph.D., president and CEO of CytoDyn, stated in the news release.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Biotechnology company CytoDyn (OTCQB: CYDY) this morning announced the featured interview of its President and CEO Nader Z. Pourhassan, Ph.D. with Stock Day's Everett Jolly. Jolly initiated the discussion by asking about CytoDyn’s PRO 140. The company’s flagship product is a humanized IgG4 monoclonal antibody that is designed to bind to cellular receptor CCR5, which plays various roles with implications in HIV, tumor metastasis and immune signaling. Pending FDA approval, which the company hopes to secure in Q4 2019, Pourhassan indicates that PRO 140 may be available to the public in 2020. "Most biotech companies, when they finish the biologic application, they have an 85% chance to get approved. 9 out of 10 who don't get approved is because of the safety of the product. Our product has received fast track designation due to having great safety among all of the approved drugs," Nader Z. Pourhassan, Ph.D., president and CEO of CytoDyn, stated in the news release.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼